Pfizer CEO slams Medicare IRA measure

Editor's Note: Fierce Biotech is monitoring the FDA's advisory meeting for Sarepta Therapeutics' DMD gene therapy. Check our website this evening for the latest news.

Today's Big News

May 12, 2023

As pharma fights IRA, Senate committee advances basket of bills aimed at lowering drug prices


GSK tees up Pfizer fight with pivotal meningitis vaccine data


Pfizer CEO Bourla slams Medicare IRA measure as 'negotiation with a gun to your head'


Ozempic and Wegovy have taken over obesity treatment. Can they help with cancer too?


Sanofi, AstraZeneca strengthen case for RSV antibody with data from real-world trial


Liver disease misinformation rampant on TikTok: study

 

Featured

As pharma fights IRA, Senate committee advances basket of bills aimed at lowering drug prices

The U.S. Senate’s Health, Education, Labor & Pensions (HELP) Committee voted on Thursday to advance a basket of bipartisan bills with the goal to tighten rules that have benefited pharma companies and pharmacy benefit managers and introduce new ones to increase transparency.
 

Top Stories

GSK tees up Pfizer fight with pivotal meningitis vaccine data

GSK has shared pivotal data that could help fend off Pfizer’s attack on its blockbuster vaccine franchise. The phase 3 results show the five-in-one meningitis vaccine is immunologically effective against the most common strains, keeping GSK tucked in behind Pfizer in the race to market.

Pfizer CEO Bourla slams Medicare IRA measure as 'negotiation with a gun to your head'

Amid reports that the pharma industry is preparing a legal challenge to drug price negotiation measures in the Inflation Reduction Act, Pfizer CEO Albert Bourla blasted the plan, calling it “negotiation with a gun to your head" at a Reuters event.

Ozempic and Wegovy have taken over obesity treatment. Can they help with cancer too?

Novo Nordisk’s Ozempic and Wegovy may have benefits beyond helping patients shed pounds: They appear to reverse the impairments in cancer-fighting natural killer cells seen in people with obesity, independent of weight loss.

Sanofi, AstraZeneca strengthen case for RSV antibody with data from real-world trial

The race is on for companies hoping to get vaccines to the market this fall for the start of the respiratory syncytial virus season. Sanofi and AstraZeneca have taken another step toward that goal, revealing strong data from a real-world trial of their candidate nirsevimab.

Liver disease misinformation rampant on TikTok: study

Around 40% of liver disease posts on social media site TikTok contain misinformation in a worrying trend doctors want to reverse.

Algorithm, Hoth call off planned alliance, sending both off into icy terrain

Algorithm Sciences is no longer planning to set up a base on Hoth Therapeutics, as the two small biotechs terminate a planned merger.

Takeda braces for impact as Vyvanse edges toward the patent cliff

Bracing for losses of exclusivity on a pair of drugs this year, Takeda has forecasted 3,840 billion yen (about $28.5 billion) in revenues for fiscal year 2023, an expected 4.7% drop from the sum the company reported in 2022.

Gritstone, MEI join biotechs using earnings season to reshuffle pipeline priorities

‘Tis the season—earnings season that is. A time of pipeline culls, project delays and partnership terminations—and this quarter has been no exception, with two more biotechs reporting changes today. 
 
Fierce podcasts

Don't miss an episode

'The Top Line': The final installment of a series on Narcan, plus this week's headlines

This week on "The Top Line," we're concluding our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.
 

Resources

Whitepaper

ChatGPT in Drug Discovery: Rise of Large Language Models

ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations.
eBook

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.
Research

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.
Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event
18-19
Jul
July 18-19, 2023 | Jersey City, NJ

View all events